01.14.15
SGS Life Science Services has completed a full analytical validation of the Meso Scale Discovery (MSD) V-PLEX 10-plex Proinflammatory Panel I for use with human plasma samples, at its lab in Poitiers, France. The validation included measurement of accuracy, recovery, dilutional linearity, and stability, using in-house and the manufacturer’s surrogate validation quality controls.
This new service offering will enable the lab to generate more information by quantification of multiple biomarkers. Also 10 assays can be conducted in parallel, saving on the volume of clinical samples required and reducing turnaround time.
The Panel measures 10 cytokines that are important in inflammatory response and immune system regulation, as well as other biological processes. It also includes assays for many of the Th1/Th2 pathway biomarkers and measures biomarkers that are implicated in various disorders, including rheumatoid arthritis, Alzheimer’s disease, asthma, atherosclerosis, allergies, systemic lupus erythematosus, obesity, cancer, depression, multiple sclerosis, diabetes, psoriasis, and Crohn’s disease.
“We have deep understanding and expertise in the use of multiplex platforms as one of the routine bioanalytical procedures for clinical testing,” said Dr. Rabia Hidi, SGS Life Science Services director of Biomarkers & Biopharmaceutical Testing. “We can produce robust data and fully validate multiplexing methods to offer both quality of data and cost convenience, while using the minimum sample volumes. Where SGS differentiates itself in this space, is that our multiplexing methods can be fully validated and used in decision making studies.”
This new service offering will enable the lab to generate more information by quantification of multiple biomarkers. Also 10 assays can be conducted in parallel, saving on the volume of clinical samples required and reducing turnaround time.
The Panel measures 10 cytokines that are important in inflammatory response and immune system regulation, as well as other biological processes. It also includes assays for many of the Th1/Th2 pathway biomarkers and measures biomarkers that are implicated in various disorders, including rheumatoid arthritis, Alzheimer’s disease, asthma, atherosclerosis, allergies, systemic lupus erythematosus, obesity, cancer, depression, multiple sclerosis, diabetes, psoriasis, and Crohn’s disease.
“We have deep understanding and expertise in the use of multiplex platforms as one of the routine bioanalytical procedures for clinical testing,” said Dr. Rabia Hidi, SGS Life Science Services director of Biomarkers & Biopharmaceutical Testing. “We can produce robust data and fully validate multiplexing methods to offer both quality of data and cost convenience, while using the minimum sample volumes. Where SGS differentiates itself in this space, is that our multiplexing methods can be fully validated and used in decision making studies.”